A 67-Year-Old Man with Chronic Lymphocytic Leukemia

John Allan, MD, presents and reviews the case of a 67-year-old man with chronic lymphocytic leukemia.

A key opinion leader shares insight into testing and risk stratification for chronic lymphocytic leukemia.

John Allan, MD, highlights treatment options in the first-line setting for chronic lymphocytic leukemia.

A leukemia specialist details the Resonate-2 clinical trial studying BTK inhibitor ibrutinib.

John Allan, MD, compares the available approved BTK inhibitors for treating chronic lymphocytic leukemia.

An expert describes various treatment approaches for patients with high-risk chronic lymphocytic leukemia.

John Allan, MD, looks to the future of chronic lymphocytic leukemia treatments.